SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions is trending due to a strategic manufacturing partnership with Syrma Johari MedTech, which aims to scale production of its fingerprinting drug screening reader and anticipates substantial cost savings. This positive news, however, is being overshadowed by a significant private placement and share offering that has fueled community concerns over potential dilution. Traders are actively debating the impact of this offering on the stock's recent volatility and future price trajectory.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is actively trending as its community eagerly anticipates the start of a new yearly cycle, with many predicting a significant bullish reversal based on historical performance. Investors are discussing aggressive accumulation, forecasting substantial long-term growth and positioning LTC as a strong contender for major appreciation in upcoming crypto market upturns.

Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Rockville, MD.

Sensei Biotherapeutics Inc

Sensei Biotherapeutics (SNSE) is experiencing significant momentum driven by its extremely low share float, fueling widespread community discussion around its potential for a short squeeze. Traders are actively accumulating shares, anticipating a parabolic breakout and new highs as volume continues to build, drawing comparisons to other recent volatile low-float stocks.

Alchemy Investments Acquisition Corp. 1 is a blank check company, which engages in merger, share exchange, asset acquisition, share purchase, and reorganization or similar business combination. The company was founded on October 27, 2021 and is headquartered in Newark, DE.

Alchemy Investments Acquisition Corp 1 - Ordinary Shares - Class A

Alchemy Investments Acquisition Corp 1 (ALCY) is actively trending as the community speculates it could be the next low-float SPAC to experience a substantial price surge, drawing parallels to recent strong performers like ESHA. Traders are enthusiastically discussing a potential significant move, driven by the broader "low float SPAC bubble" theme and the perceived ease of high-percentage gains. This collective anticipation is fueling positioning and elevated trading activity.

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESHA is trending as a low-float SPAC, sparking widespread community discussion about its potential for explosive upward movement. Traders are actively debating whether it will follow the recent parabolic runs seen in similar micro-float companies, with many advocating for holding positions amid high volatility. The conversation emphasizes the stock's thin order book and the perceived impact of high insider ownership on its price action.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending upward following significant regulatory updates, including the FDA's priority review of AXS-05 for Alzheimer's disease agitation and positive feedback supporting an NDA submission for AXS-12 in narcolepsy. The community is buzzing with excitement, celebrating these milestones as pivotal catalysts that could drive substantial market expansion and propel the company toward future growth, particularly given the high impact of Alzheimer's-related treatments.

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

Aquestive Therapeutics Inc

Aquestive Therapeutics is trending with high anticipation ahead of Anaphylm's pivotal FDA decision on January 31, 2026, for its novel, device-free epinephrine film. Community discussion is vibrant, with many confident in approval citing strong clinical data and a waived advisory committee, while others express caution due to historical regulatory setbacks and a notable short interest. The market keenly watches if Anaphylm will significantly disrupt the existing anaphylaxis treatment landscape, challenging rivals like SPRY.

DoubleZero is a high-performance global network of independently contributed links, purpose-built for blockchain and other distributed systems. It provides direct, low-latency routing that strengthens validator performance and supports faster, fairer participation worldwide.  2Z Tokens are used to access the network’s connectivity service, and, on the other side, reward network contributors and resource providers based on performance and reliability. 2Z Tokens can also be staked to enhance the security of the network.

DoubleZero

DoubleZero ($2Z) is trending amidst buzz regarding new listings on major crypto exchanges, which is fueling significant trading volume. The community is actively discussing its fiber optics technology, anticipating substantial altseason gains, though some express caution regarding its rapid volatility.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

Ondas Holdings (ONDS) is trending after announcing $10 million in new autonomous systems orders, a key catalyst driving significant bullish sentiment among investors. The community is buzzing with optimism about the company's strong position in the growing global counter-drone and autonomous defense sectors, anticipating further substantial contract awards and growth in 2026. This positive outlook is further bolstered by the recent launch of a 2x long ETF specifically tracking ONDS.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai (BBAI) is actively trending following the announced completion of its Ask Sage acquisition, a strategic move aimed at enhancing its secure generative AI capabilities for government and regulated industries. This development is sparking community discussion around its potential to secure significant government contracts, particularly for defense and airport security, amidst ongoing debates regarding upcoming shareholder votes on dilution and the stock's future trajectory within the AI-driven government tech sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Short Interest in AC Immune (NASDAQ:ACIU) Grows By 94.4%

AC Immune (NASDAQ:ACIU - Get Free Report) was the recipient of a significant increase in short interest in the month of December. As of December 15th, there was short interest totaling 3,593,227...

AC Immune (NASDAQ:ACIU) Trading Up 5% - Should You Buy?

AC Immune (NASDAQ:ACIU) Trading 5% Higher - Here's What Happened...

<ul class="summary-bullets"><li>The trial results showed for the first time that active immunotherapy targeting a-syn pathology could slow the progression of Parkinson’s disease.&nbsp;</li><li>The interim results from the study showed a 100% responder rate for all targets.</li><li>ACIU plans to seek regulatory feedback to potentially speed up the clinical development path towards registration.&nbsp; &nbsp;</li></ul>AC Immune SA (ACIU) shares surged on Thursday morning after the biopharma company announced positive results from the interim Phase 2 study of its early Parkinson’s disease treatment.&nbsp;The company said that the results of the VacSYn trial of ACI-7104.056 showed, for the first time, that targeting a-syn pathology with an active immunotherapy could possibly slow the progression of Parkinson’s disease.&nbsp;Shares of&nbsp;<a href="https://stocktwits.com/symbol/ACIU">ACIU</a> surged over 23% in pre-market trading after the announcement.&nbsp;“The interim Phase 2 data shows the potential of our ACI-7104.056 active immunotherapy to slow the progression of Parkinson’s disease and hold the promise of a tremendous step forward for millions of patients,” said Andrea Pfeifer, CEO of AC Immune SA. Pfeifer added that the strong results would be a basis for accelerating the development of the treatment.&nbsp;<h2 class="st-heading-2">Study Results</h2>The interim results from the study showed that the company’s new treatment had a 100% responder rate, meaning all participants had the expected immune response across all immunogenicity measures used.There were no clinically relevant or serious adverse effects to the drug apart from routine side effects such as injection site reactions, headaches, and fatigue, as reported by some participants.&nbsp;Final results from the Part 1 trial are expected in mid-2026, and the company plans to seek regulatory feedback to potentially speed up the clinical development path towards registration.&nbsp;<h2 class="st-heading-2">How Are Stocktwits Users Reacting?</h2>On Stocktwits, retail sentiment around ACIU jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume jumped to ‘extremely high’ from ‘normal’ levels at the time of writing.<figure class="image"><img style="aspect-ratio:1282/158;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_11_at_7_36_27_PM_png_161653af50.webp" alt="ACIU sentiment and message volume" width="1282" height="158"></figure>Shares of ACIU are up over 31% in the past six months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

CHINA - 2025/10/02: In this photo illustration, the AC Immune logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Why Is AC Immune Stock Up Over 23% Today?

ACIU shares surged over 23% after the company announced positive results from an interim Phase 2 study. 

Equity

FY2025 EPS Estimates for AC Immune Lifted by HC Wainwright

AC Immune (NASDAQ:ACIU - Free Report) - Investment analysts at HC Wainwright increased their FY2025 earnings per share (EPS) estimates for AC Immune in a report issued on Wednesday, November 5th. HC...

FY2025 EPS Estimates for AC Immune Raised by Leerink Partnrs

AC Immune (NASDAQ:ACIU - Free Report) - Investment analysts at Leerink Partnrs increased their FY2025 earnings per share (EPS) estimates for AC Immune in a research note issued on Wednesday, November...

AC Immune (ACIU) Reports Q3 Loss, Lags Revenue Estimates

AC Immune (ACIU) delivered earnings and revenue surprises of +9.09% and -22.51%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Alector (ALEC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: AC Immune (ACIU) Q3 Earnings Expected to Decline

AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Intellia Therapeutics (NTLA) Soars 19.7%: Is Further Upside Left in the Stock?

Intellia Therapeutics (NTLA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

New Strong Sell Stocks for August 6th

ACIU, ABEV and ALX have been added to the Zacks Rank #5 (Strong Sell) List on August 6, 2025.

AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.

ACIU
AC Immune SA

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ACIU News

ACIUAC Immune SA